Clinical validation of the Cervista HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology.
about
Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesionsHPV-Testing in Follow-up of Patients Treated for CIN2+ LesionsClinical significance of human papillomavirus genotypingHuman papillomavirus and cervical cancer: biomarkers for improved prevention effortsThe interplay of age stratification and HPV testing on the predictive value of ASC-US cytology. Results from the ATHENA HPV study.Carcinogenicity of Human Papillomavirus (HPV) Types in HIV-Positive Women: A Meta-Analysis From HPV Infection to Cervical Cancer.Improved sensitivity of vaginal self-collection and high-risk human papillomavirus testing.Comparing the Cervista HPV HR test and Hybrid Capture 2 assay in a Dutch screening population: improved specificity of the Cervista HPV HR test by changing the cut-off.Usefulness of serum mass spectrometry to identify women diagnosed with higher grades of cervical intraepithelial neoplasia may differ by raceLong-term cumulative detection of human papillomavirus among HIV seropositive women.Clinical experience with the Cervista HPV HR assay: correlation of cytology and HPV status from 56,501 specimensCervical Cancer Tests and Treatment.Biomarkers of cervical dysplasia and carcinomaComparison of the Seeplex HPV4A ACE and the Cervista HPV assays for the detection of HPV in hybrid capture 2 positive media.Establishment of immunoassay for detecting HPV16 E6 and E7 RNA.Effect of glacial acetic acid treatment of liquid-based cytology collections on performance of Cervista HPV HR for detection of high-risk human papillomavirus.A review of methods for detect human Papillomavirus infectionHuman Papillomavirus Laboratory Testing: the Changing ParadigmTriage of HPV positive women in cervical cancer screening.Five-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results.HPV-based Tests for Cervical Cancer Screening and Management of Cervical Disease.Risk of precancer determined by HPV genotype combinations in women with minor cytologic abnormalitiesClinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up.Commercially available assays for multiplex detection of alpha human papillomaviruses.Human papilloma virus (HPV) molecular diagnostics.Type 1 and type 2 cervical carcinomas: some cervical cancers are more difficult to prevent with screening.Molecular approaches for HPV genotyping and HPV-DNA physical status.Clinical validation of the PCR-reverse dot blot human papillomavirus genotyping test in cervical lesions from Chinese women in the Fujian province: a hospital-based population study.Histopathologic follow-up and HPV test results with HSIL Papanicolaou test results in China's largest academic women's hospital.Comparative study of the cervista and hybrid capture 2 methods in detecting high-risk human papillomavirus in cervical lesions.Clinical laboratory experience with cervista HPV HR as a function of cytological classification: comparison with retrospective digene HC2 high-risk HPV DNA test data.
P2860
Q24198236-41A590CC-CC38-456A-8628-11D083F2DDD4Q26771420-51B9EB85-5EF3-46E8-9FAD-F5C6A5591531Q26771981-DB59E89C-6F57-40BF-AA36-875FC13A72B2Q27023127-DF85EB94-8D96-44D5-8352-DCA5CAF7DA61Q30454956-D97C8A33-BCCE-49DA-9241-5F80278E252EQ33589259-96EA27EC-9327-4AC4-9061-F4D4AC82FB64Q33918589-6C5DE232-4C11-4B65-B26D-AF7E03B6E371Q33933176-3CE8E810-2260-4298-ADA5-D3B004566032Q33972558-54938918-D238-4384-AD0E-8F2CE0B4E852Q34899459-8FCAE4D1-FA91-43C5-856A-A387CD437878Q35083587-F7A8C65E-A28B-46AE-8800-AE1E7E903954Q35124947-F7BAF48E-8EC7-4374-9AED-D254143934EBQ35495173-ED66BF41-CB60-48C0-A1A2-CB3B6918E824Q35758717-4EE00F96-4015-4E88-B932-80E7A38AFA69Q36022496-1D5183F3-AC25-44FF-BDE9-186646605F2CQ36022846-4E6324F4-3158-4C4D-8A01-5FE02174B3EEQ36427451-5F05BEFE-FA00-4D95-A019-0CD27AF5DE17Q36675236-A70789D8-145B-4158-B73F-684520D77372Q36679896-00BB40CE-4287-4DF4-8C07-E320A09D94FBQ36740209-E6681626-FA28-4F79-B2F4-3C6ECEECF842Q36856284-FB7F04AB-F024-4133-9910-E7BEEFED164BQ36941977-E73CFD9C-F62C-4EEE-8972-3923E0FF3B12Q37065936-93B841AA-1664-4943-9AE9-5E5A1F7DA854Q37800921-04B07C05-4C4E-42D8-9754-0753790D69B2Q37923517-4B54CEE7-3309-4492-B81C-BCE3B7E6D1B9Q37975557-82479C32-8D08-492A-A891-F34BB5DE77A3Q39120200-1144B339-5AE6-490B-9C45-D5A08B6DBB47Q40155311-510F9EF9-464F-47A5-AF92-373DEC9FC2ABQ40503813-E345A7AB-ED2C-44B5-88E4-E6C4BC9B74A7Q42279932-7527BFCA-14DA-40E9-8361-3196316A7EB3Q43233441-CAEB542C-77FF-4877-A630-F8712802D8DF
P2860
Clinical validation of the Cervista HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 May 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical validation of the Cer ...... in women with ASC-US cytology.
@en
Clinical validation of the Cer ...... in women with ASC-US cytology.
@nl
type
label
Clinical validation of the Cer ...... in women with ASC-US cytology.
@en
Clinical validation of the Cer ...... in women with ASC-US cytology.
@nl
prefLabel
Clinical validation of the Cer ...... in women with ASC-US cytology.
@en
Clinical validation of the Cer ...... in women with ASC-US cytology.
@nl
P2093
P1433
P1476
Clinical validation of the Cer ...... in women with ASC-US cytology.
@en
P2093
Amy L Mitchell
Daron G Ferris
Francisco A R Garcia
Marilyn C Olson
Mark G Martens
Mark H Einstein
Stephen P Day
P304
P356
10.1016/J.YGYNO.2010.04.013
P407
P577
2010-05-21T00:00:00Z